# Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

> **NCT04028778** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 310 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Anlotinib Hydrochloride
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04028778
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-10
- **Primary completion:** 2020-12
- **Final completion:** 2022-12
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04028778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04028778, "Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04028778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*